4.2 Review

Treatment review for male pattern hair-loss

Journal

EXPERT OPINION ON PHARMACOTHERAPY
Volume 21, Issue 5, Pages 603-612

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/14656566.2020.1721463

Keywords

Androgenetic alopecia; 5-alpha-reductase inhibitors; finasteride; male pattern hair loss; minoxidil

Funding

  1. Leo Pharma
  2. Amgen Inc
  3. Novartis
  4. Merck Co.
  5. Celgene
  6. Coherus Biosciences
  7. Janssen Pharmaceuticals
  8. Regeneron
  9. MedImmune
  10. GlaxoSmithKline
  11. Cutanea
  12. Samson Clinical
  13. Boehringer Ingelheim
  14. Pfizer Inc
  15. Merck Sharp and Dohme
  16. Oncobiologics
  17. Roche
  18. Eli Lilly and Company
  19. Bayer Healthcare

Ask authors/readers for more resources

Introduction: Androgenetic alopecia is a common hair loss disorder affecting up to 80% of males by the age of 80. It is characterized by androgen related progressive thinning of hair in a defined pattern. It results in diminished self-esteem, reduced confidence and distress in affected men, irrespective of age or stage of baldness. An effective treatment for hair baldness is needed. Areas covered: In androgenetic alopecia, hair follicles undergo progressive miniaturization. Genetic factors and androgens are key role-players in disease pathogenesis. Herein the authors review the pharmacologic treatment of androgenetic alopecia, which involves 5 alpha reductase inhibitors, minoxidil and prostaglandins. Non-pharmacologic approaches are also explored. Expert opinion: Androgenetic alopecia progresses over time and although the current available medical treatments like finasteride and minoxidil are effective in arresting the progression of the disease, they allow only partial regrowth of hair at its best. Early treatment achieves a more optimal outcome. Non-pharmacologic treatments like PRP can be considered in patients refractory to medical treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available